PT  - JOURNAL ARTICLE
AU  - DANOVA, MARCO
AU  - BENCARDINO, KATIA
AU  - MANZONI, MARIANGELA
AU  - GRASSO, DONATELLA
AU  - MARIUCCI, SARA
AU  - ROVATI, BIANCA
TI  - <em>In Vivo</em> Biological Effects of Pegfilgrastim after Myelosuppressive Chemotherapy in Breast Cancer
DP  - 2007 Sep 01
TA  - Anticancer Research
PG  - 3399--3402
VI  - 27
IP  - 5A
4099  - http://ar.iiarjournals.org/content/27/5A/3399.short
4100  - http://ar.iiarjournals.org/content/27/5A/3399.full
SO  - Anticancer Res2007 Sep 01; 27
AB  - Background: No exhaustive data are available on the in vivo biological effects of pegfilgrastim utilized in dose-dense chemotherapy (CT). The cytokinetic effects exerted in a multicyclic CT program by this cytokine on CD34+/38+ peripheral blood (PB) progenitor cells was the focus of this study. Patients and Methods: PB samples from 19 breast cancer patients treated with 4 courses of docetaxel and epirubicin followed by pegfilgrastim were studied. The absolute number of CD34+/38+ circulating progenitor cells (CPCs) along with the percentage undergoing G0/G1, S and G2-M phases of the cell cycle or showing apoptotic features, were evaluated at baseline, after the first and before the fourth CT course using a dedicated flow cytometric technique. Results and Conclusion: Pegfilgrastim, after CT, exerted stimulatory effects on the cell cycle status of PB CD34+/38+ CPCs, at the same time protecting them from apoptosis. This was particularly evident 7 days after administration and tended to decrease one week later, without additional cytokinetic changes during the subsequent CT courses. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved